[Remote] Director, Early Clinical Development - Nephrology/Immunology (N/I)

Note: The job is a remote job and is open to candidates in USA. Otsuka Pharmaceutical Companies (U.S.) is seeking a Director for Early Clinical Development focusing on Nephrology and Immunology. This strategic role involves leading early clinical development strategies and execution for Otsuka's early phase portfolio, particularly in immunologic and inflammatory diseases, while collaborating with various teams to ensure effective integration across functions.ResponsibilitiesServe as scientific and clinical expert in N/I translational medicine and early clinical development, contributing to strategic program decisions; serve as ECD lead on development teams for multiple assetsDrive Research-to-Development (R2D) strategies and stage-gate decision-making, including indication prioritization and go/no-go based on mechanistic rationale, benefit-risk, and clinical unmet need as well as on clinical and/or biomarker driven endpoints. Prepare and present decision-quality data packages for internal governance reviews to support stage-gate decisionsInteract with internal and external groups to evaluate new compounds, molecular and biological targets as well as new formulation technologiesPartner with internal and external research organizations to expand and facilitate development of early phase and discovery phase compounds. Engage with external experts and key opinion leaders to inform translational and Proof of Concept (PoC) strategy and maintain scientific leadershipRepresent ECD in cross functional as well as internal/external collaborations (BD, etc.) on activities related to early phase target and asset identification. Support regulatory interactions (e.g., pre-IND, IND submissions) and ensure translational strategies align with regulatory requirementsLead scientific and clinical development efforts for assigned programs from target identification through IND and proof-of-concept. Provide medical leadership for early-phase clinical protocols, informed consent forms, and investigator brochures; monitor safety and contribute to DSMB or safety review activities as neededSupport or lead public-private partnerships operating in pre-competitive settings to advance internal clinical development capabilitiesInteract with other disciplines within the EDO to promote, initiate and elevate cross-functional early development activities. Collaborate with biomarker and digital innovation teams to develop and implement biomarker-driven approaches for N/I programsSupport the development of team members to build translational and early clinical development expertiseSkillsMD or MD/PhD with specialty/ training in nephrology, rheumatology or immunology. Dermatologists with immunologic/inflammatory skin disease expertise may also be considered5+ years of translational medicine and/or early clinical development experience with a track record of advancing biologics and/or small molecules through IND and FIH/PoCExpert understanding of industry best practices and adjacent functional areasDemonstrated ability to coordinate and guide cross-functional teams in matrixed, global setting, with solid strategic thinking and the ability to make informed decisions amid uncertaintyOutstanding communication skills with the ability to synthesize complex data and influence executive stakeholdersDeep expertise in N/I, particularly nephrology, rheumatology or immunologyExperience implementing clinical study plans to drive decision-makingExperience with external collaborationsBenefitsComprehensive medical, dental, vision, prescription drug coverageCompany provided basic life, accidental death & dismembermentShort-term and long-term disability insuranceTuition reimbursementStudent loan assistanceA generous 401(k) matchFlexible time offPaid holidaysPaid leave programsOther company provided benefitsCompany OverviewThere are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. It was founded in 1989, and is headquartered in Rockville, Maryland, USA, with a workforce of 1001-5000 employees. Its website is https://www.otsuka-us.com.Company H1B SponsorshipOtsuka Pharmaceutical Companies (U.S.) has a track record of offering H1B sponsorships, with 2 in 2026, 8 in 2025, 6 in 2024, 11 in 2023, 5 in 2022, 9 in 2021, 13 in 2020. Please note that this does not guarantee sponsorship for this specific role.